Psychosocial Screening for Neuroendocrine Tumor Patients

NCT03372356 | Unknown DMC

• 1 other identifier: PSNET
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

This is a psychosocial screening application to usual care in a cohort of neuroendocrine tumor patients. The application involves monitoring using the NCCN Distress Thermometer(DT), Hospital Anxiety and Depression Scale(HADS), Self-Perceived Burden Scale(SPBS) and Connor-Davidson Resilience Scale(CD-RISC). These assessments will be completed at baseline, 3 months, 6 months, 12 months and 24 months. Patients will have the option of filling out questionnaires more frequently if desired.

Conditions

Neuroendocrine Tumors

Keywords

DT; HADS; SPBS; CD-RISC; Psychosocial Screening

Outcome Measures

Primary Outcomes (1)

• DT

  Distress Thermometer

  every 3 month until 24 month

Secondary Outcomes (3)

• HADS

  every 3 month until 24 month

• SPBS

  every 3 month until 24 month

• CD-RISC

  every 3 month until 24 month

Study Arms (1)

Neuroendocrine tumors

Patients with neuroendocrine tumors will be given access to an application that monitors distress, anxiety, depression, self-perceived burden, and resilience at regular intervals for 3 months lasting for 24 months.

Eligibility Criteria

• Age: 18 Years+
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with well-differentiated neuroendocrine tumors, G1-2 (Ki67≤20%)

You may qualify if:

• sign written informed consent form;
• age ≥ 18 years;
• pathologically confirmed well-differentiated neuroendocrine tumors, G1-2 (Ki67≤20%);

You may not qualify if:

• \<18 years;
• Neuroendocrine carcinoma;
• History of psychiatric or psychologic illness;
• History of previous cancers or cancer distress;
• Patients with central nervous system(CNS) disorder；
• Severe, uncontrolled medical condition that would affect patients' compliance;

Sponsors & Collaborators

• Peking University: lead

Study Sites (1)

Beijing Cancer Hospital

Beijing, Beijing Municipality, 100142, China

RECRUITING

MeSH Terms

Conditions

Neuroendocrine Tumors

Condition Hierarchy (Ancestors)

Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Nerve Tissue

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD, Professor, Chief of Department of GI Oncology, Peking University Cancer Hospital

Study Record Dates

• First Submitted: December 10, 2017
• First Posted: December 13, 2017
• Study Start: August 9, 2017
• Primary Completion: August 9, 2019
• Study Completion: August 9, 2020
• Last Updated: December 13, 2017

Record last verified: 2017-08

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)